The detection of hTERC amplification using fluorescence in situ ...
Recommend Documents
mary differences in the stage of tumor progression between various tumors. ... Look AT, Hayes FA, Shuster JJ, Douglass EC, Castle- berry RD, Bowman LC, ...
Feb 11, 2014 - 2014 Gabba et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons. Attribution ...
detection of high-grade cervical intraepithelial neoplasia. (CIN), which is the precursor of invasive cervical squamous cell carcinoma. It is a major challenge in ...
âerbB-2,â or âHER2/neuâ and âpancreatic neoplasms,â. âsurvival,â and âprognosis.â In the study, electronic search engines were used for searching: PubMed, ...
Dec 30, 2010 - fluorescence in situ hybridization on chromosomes of ... Key words: Hydra magnipapillata, karyotype, chromosomes, fluorescence in situ.
A MULTICENTER PHASE III RANDOMIZED TRIAL COMPARING DOCETAXEL IN ...... All included patients in both arms will receive a fixed number of cycles of treatment. ⢠TAC x 6 .... a) Congestive heart failure or unstable angina pectoris, previous history o
&p.1:Abstract We have used horseradish peroxidase-labeled. 40 mer oligodeoxynucleotides (HRP-ODNs) specific for the human cytomegalovirus immediate ...
Beauchamp2, J.L. Beauchamp1. E-mail: [email protected]. 1Noyes Laboratory of Chemical Physics, California Institute of Technology, Pasadena,. CA 91125.
thereby boosting detection sensitivity by orders of magnitude, and apply the approach to several life science applications. We achieve fluorescence amplification ...
submitted). CosLIF is a 45 kb cosmid for the Leukaemia. Inhibitory Factor, isolated using a 300 bp probe derived from the LIF exon (Gough et al., 1988; Budarf et ...
two additional libraries (SD and Time) that are available online. Prior to ... The name of the text file must correspond to the one found in the Arduino script.
Jun 14, 2018 - rearrangement in nonsmall cell lung carcinoma. Mohamed Hantera a ..... adenopathy, lymphangitic carcinomatosis, and pericardial or pleural ...
some instances the correct interpretation on the nature of these changes may be ... analysis by rapidly and unambiguously delin- ... occasional blood test displaying a moderate .... Bartram CR, Anger B, Carbonell F, Kleihauer E . Involvement.
... in situ hybridization. Detection of monosomy 7 and trisomy 8 in myeloid neoplasia: a ... acute myeloid leukemia (AML) are monosomy 7 (-7) and trisomy 8 (+8). ...... mans JC, Van Krieken JHJM, Kok F, Kluin PM: Mosaicism of trisomy 12 in ...
the location of several critical genes in prostate can- cer. For example, initial evidence of nonrandom prostate cancer chromosome aberrations included.
Jan 27, 2010 - the classes Deltaproteobacteria (5.8 to 28.3%) and Gammaproteobacteria (1.2 to 8.2%). All were more .... sharpened in Adobe Photoshop CS3.
Jun 16, 2016 - presence of numerous and recurrent chromosomal imbalances ... Key words: melanoma, nevus, chromosome, fluorescence in situ.
Abstract. Urothelial carcinomas arising from the upper urinary tract (renal pelvis and ureter) are rare and few molecular genetic studies of these tumors have.
analysis and fluorescence in situ hybridization (FISH) in cases with ..... oratories recently have adopted the âFISH-aloneâ approach, we are currently working to ...
extracted nuclei from snap frozen buffy coat stored for the purpose of molecular ... by lysing erythrocytes with lysing solution (LYSE S III DIFF, Coulter Corp.).
Nov 13, 2013 - Paralytic shellfish poisoning (PSP) is a type of seafood poisoning due to consumption of shellfish molluscs contaminated by neurotoxins ...
amplification, since any actual disc will return some reflected light, thus ..... to bounce back and forth between the faces until it finally strikes the black edge.
of the granules by using fluorescent oligonucleotide probes specific to ... hybridized with coccoid cells in the inner layer of the mesophilic granule sections.
called amplified spontaneous emission, super fluorescence, or - incorrectly. - superradiance). Fluorescence amplification makes energy storage in lasers more ...
The detection of hTERC amplification using fluorescence in situ ...
The detection of hTERC amplification using fluorescence in situ hybridization in the diagnosis and prognosis of cervical intraepithelial neoplasia: a case control ...
Yin et al. World Journal of Surgical Oncology 2012, 10:168 http://www.wjso.com/content/10/1/168
RESEARCH
WORLD JOURNAL OF SURGICAL ONCOLOGY
Open Access
The detection of hTERC amplification using fluorescence in situ hybridization in the diagnosis and prognosis of cervical intraepithelial neoplasia: a case control study Geping Yin*, Juan Li, Tongyu Zhu and Xiaoli Zhao
Abstract Background: Currently the routine non-invasive screening methods for cervical intraepithelial neoplasia (CIN) and cervical cancer are Thinprep cytology test (TCT) and human papillomavirus testing. However, both methods are limited by the high false positive and false negative rates and lack of association with patients’ prognosis, especially for the early detection of pro-malignant CIN. The aim of the study was to investigate the role of genomic amplification of human telomerase gene (hTERC) in the diagnosis and prognosis of CIN. Methods: The study group consisted of specimens of exfoliated cervical cells from 151 patients, including 27 with CIN I, 54 with CIN II/III, 17 with carcinoma in situ, and 28 with invasive squamous carcinoma, as well as 25 patients who were at 2-year follow-up after either Loop Electrosurgical Excision treatment (n = 11) or radical surgery (n = 14). hTERC amplification was detected by dual-color interphase fluorescence in situ hybridization (FISH), and the results were compared with TCT and histologic examination. The final diagnosis was determined by the pathological examination. The control group consisted of specimens of exfoliated cervical cells from 40 normal women. Results: The percentage of cervical exfoliated cells with positive hTERC amplification and incidence rates of hTERC amplification were 9.2% ± 4.6% and 44.4% (12/27) respectively in patients with CIN I; 16.0% ± 14.4% and 85.1% (46/54) in patients with CIN II/III; 19.7% ± 13.3% and 88.3% (15 /17) in patients with carcinoma in situ; 47.0% ± 25.2% and 100% (28/28)in patients with invasive squamous carcinoma. There was statistically significant difference between the control and study group (P
